Integra Lifesciences Holdings Corp (NASDAQ:IART) Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $51.56, for a total value of $807,326.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Integra Lifesciences stock opened at $49.82 on Thursday. Integra Lifesciences Holdings Corp has a 12-month low of $42.14 and a 12-month high of $67.50. The company has a market cap of $4.31 billion, a PE ratio of 20.59, a P/E/G ratio of 1.46 and a beta of 0.90. The company has a current ratio of 2.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.95.

Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a return on equity of 15.60% and a net margin of 5.60%. The company had revenue of $359.69 million for the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter in the prior year, the business posted $0.58 EPS. The business’s revenue was up .7% compared to the same quarter last year. As a group, equities analysts expect that Integra Lifesciences Holdings Corp will post 2.7 earnings per share for the current fiscal year.

Several equities research analysts have commented on IART shares. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Monday, February 18th. Oppenheimer cut their target price on Integra Lifesciences from $70.00 to $65.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. ValuEngine upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a research note on Wednesday, February 13th. Morgan Stanley set a $57.00 target price on Integra Lifesciences and gave the company a “hold” rating in a research note on Friday, February 22nd. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $50.00 target price on shares of Integra Lifesciences in a research note on Thursday, February 21st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $59.42.

Several institutional investors have recently made changes to their positions in IART. Schonfeld Strategic Advisors LLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $461,000. One Wealth Advisors LLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $94,000. Man Group plc increased its holdings in shares of Integra Lifesciences by 71.6% during the 1st quarter. Man Group plc now owns 72,287 shares of the life sciences company’s stock worth $4,028,000 after acquiring an additional 30,154 shares during the last quarter. Jefferies Group LLC acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $994,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Integra Lifesciences during the 1st quarter worth approximately $600,000. Institutional investors own 84.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Integra Lifesciences Holdings Corp (IART) Director Sells 15,658 Shares of Stock” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/insider-selling-integra-lifesciences-holdings-corp-iart-director-sells-15658-shares-of-stock/3011795.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: What are different types of coverage ratios?

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.